TC BioPharm’s biobanks have been developed to provide a base for clinical development of cost-effective, safe and efficacious cancer treatments. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project is supported by funding from the European Union’s Horizon 2020 (H2020) Research and Innovation program via a €4million grant, the largest such EU award to any UK company for development of a healthcare therapeutic product. The GDT cell banks are collected and stored from healthy donors, providing a source for TCB to manufacture next-generation ‘off-the-shelf’ GDT cell therapies for future clinical product development.


Advantages of Using Allogeneic Cell Banks:

  • Hundreds of patients can be treated from a single donor.
  • Campaign manufacturing allows for lower cost manufacturing and consequently lower sale price which increases patient access and decreases burden on healthcare systems.
  • Donors can be selected to ensure that the GDT cells have the ideal drug properties.
  • Reproducible manufacturing allows for consistent safety and potency.

These cell banks allow us to develop better products to reach more patients.